Pristiq Tapering Guide
desvenlafaxine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Overview
Desvenlafaxine is the active metabolite of venlafaxine, formulated as an extended-release SNRI for major depressive disorder. It was designed to provide more predictable pharmacokinetics by bypassing CYP2D6 metabolism.
25mg, 50mg, 100mg
Extended-release tablets: 25mg, 50mg, 100mg
Category C (risk cannot be ruled out)
Mechanism of Action
Serotonin-norepinephrine reuptake inhibitor (SNRI). Inhibits both the serotonin and norepinephrine transporters. Unlike its parent compound venlafaxine, it does not require CYP2D6 activation.
Taper Notes
Extended-release tablets cannot be split. Compounding pharmacy needed for doses between available strengths.
Hyperbolic Tapering Guidance
Tablets cannot be crushed/split. Compounding pharmacy essential for fine reductions.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (serotonin syndrome risk)
- Serotonergic drugs increase serotonin syndrome risk
- Weak inhibitor of CYP2D6; minor effect on CYP2D6 substrates
Food Interactions
- No significant food effect on pharmacokinetics
- Avoid alcohol during treatment
Contraindications
- MAOIs within 14 days
- Known hypersensitivity to desvenlafaxine or venlafaxine
Toxicity
Serotonin syndrome with serotonergic combinations. Sustained hypertension. Lipid elevations reported. Severe discontinuation syndrome similar to venlafaxine.
Pharmacokinetics
ADME Profile
Bioavailability ~80%. Tmax ~7.5 hours. Food does not significantly affect pharmacokinetics.
~3.4 L/kg
Hepatic conjugation (UGT) and to a minor extent CYP3A4-mediated oxidation. Does not rely on CYP2D6 for activation.
Renal (~45% unchanged, ~24% as glucuronide conjugate). Total urinary recovery ~~70%.
~30%
~215 mL/min (total body clearance)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Pristiq (desvenlafaxine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.